SEARCH

SEARCH BY CITATION

References

  • 1
    Yeo CJ, Yeo TP, Hruban RH, et al. Cancer of the Pancreas, in DeVitaVT, HellmanS, RosenbergSA (eds). Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2004: 945986.
  • 2
    Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 1030.
  • 3
    Ries LAG, Eisner MP, Kosary CL, et al. SEER cancer statistics review, 1975-2002. Available at: http://seer.cancer.gov/csr/1975_2002/. Accessed June 1, 2005.
  • 4
    Yamaguchi K, Enjoji M, Tsuneyoshi M. Pancreatoduodenal carcinoma: A clinicopathologic study of 304 patients and immunohistochemical observation for CEA and CA 19-9. J Surg Oncol 1991; 47: 148154.
  • 5
    Nix GAJJ, Dubbelman C, Wilson JHP, et al. Prognostic implications of tumor diameter in carcinoma of the head of the pancreas. Cancer 1991; 67: 529535.
  • 6
    Yamaguchi K, Nishihara K, Tsuneyoshi M. Non-icteric pancreas head carcinoma fares worse than icteric pancreas head carcinoma. J Surg Oncol 1992; 49: 253258.
  • 7
    DiMagno EP. Pancreatic cancer: clinical presentation, pitfalls, and early clues. Ann Oncol 1999; 10(Suppl 4)): 140142.
  • 8
    Royal RE. The multimodality treatment of patients with pancreatic cancer. Principles Practice Oncol Updates 2004; 18: 116.
  • 9
    Tabuchi T, Itoh K, Ohshio G. Tumor staging of pancreatic adenocarcinoma using early- and late-phase helical CT. AJR Am J Roentgenol 1999; 173: 375380.
  • 10
    Spitz FR, Abbruzzese JL, Lee JE. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997; 15: 928937.
  • 11
    Saldinger PF, Reilly M, Reynolds K, et al. Is CT angiography sufficient for prediction of resectability of periampullary neoplasms? J Gastrointest Surg 2000; 4: 233237.
  • 12
    Valls C, Andia E, Sanchez A, et al. Dual-phase helical CT of pancreatic adenocarcinoma: assessment of resectability before surgery. AJR Am J Roentgenol 2002; 178: 821826.
  • 13
    Wiersema MJ. Accuracy of endoscopic ultrasound in diagnosing and staging pancreatic carcinoma. Pancreatology 2001; 1: 625632.
  • 14
    Raut CP, Grau AM, Staerkel GA, et al. Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration in patients with presumed pancreatic cancer. J Gastrointest Surg 2003; 7: 118126.
  • 15
    Murr MM, Sarr MG, Oishi AJ, et al. Pancreatic cancer. CA Cancer J Clin 1994; 44: 304318.
  • 16
    Aliperti G. Complications related to diagnostic and therapeutic endoscopic retrograde cholangiopancreatography. Gastrointest Endosc Clin N Am 1996; 6: 379407.
  • 17
    Zdravka Medarova, Moore A. Imaging of pancreatic cancer: a promise for early diagnosis through targeted strategies. Cancer Therapy 2004; 2: 329344.
  • 18
    Sheridan MB, Ward J, Guthrie JA, et al. Dynamic contrast-enhanced MR imaging and dual-phase helical CT in the preoperative assessment of suspected pancreatic cancer: a comparative study with receiver operating characteristic analysis. AJR Am J Roentgenol 1999; 173: 583590.
  • 19
    Ahmad NA, Lewis JD, Siegelman ES, et al. Role of endoscopic ultrasound and magnetic resonance imaging in the preoperative staging of pancreatic adenocarcinoma. Am J Gastroenterol 2000; 95: 19261931.
    Direct Link:
  • 20
    Malesci A, Balzarini L, Chiti A, et al. Pancreatic cancer or chronic pancreatitis? An answer from PET/MRI image fusion. Eur J Nucl Med Mol Imaging 2004; 31: 1352.
  • 21
    Zimny M, Schumpelick V. Fluorodeoxyglucose positron emission tomography (FDG-PET) in the differential diagnosis of pancreatic lesions. Chirurg 2001; 72: 989994.
  • 22
    Zimny M, Bares R, Fass J, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med 1997; 24: 678682.
  • 23
    Sperti C, Pasquali C, Chierichetti F, et al. 18-Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma. J Gastrointest Surg 2003; 7: 953959.
  • 24
    Pietrabissa A, Caramella D, Di Candio G, et al. Laparoscopy and laparoscopic ultrasonography for staging pancreatic cancer: critical appraisal. World J Surg 1999; 23: 9981002.
  • 25
    Fernandez-del Castillo C, Rattner DW, Warshaw AL. Further experience with laparoscopy and peritoneal cytology in the staging of pancreatic cancer. Br J Surg 1995; 82: 11271129.
  • 26
    Li D, Xie K, Wolff R, et al. Pancreatic cancer. Lancet 2004; 363: 10491057.
  • 27
    Willett CG, Lewandrowski K, Warshaw AL, et al. Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann Surg 1993; 217: 144148.
  • 28
    Kelsen DP, Portenoy R, Thaler H, et al. Pain as a predictor of outcome in patients with operable pancreatic carcinoma. Surgery 1997; 122: 5359.
  • 29
    Nishimura Y, Hosotani R, Shibamoto Y, et al. External and intraoperative radiotherapy for resectable and unresectable pancreatic cancer: analysis of survival rates and complications. Int J Radiat Oncol Biol Phys 1997; 39: 3949.
  • 30
    Millikan KW, Deziel DJ, Silverstein JC, et al. Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg 1999; 65: 618623.
  • 31
    Lowy AM, Lee JE, Pisters PW, et al. Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. Ann Surg 1997; 226: 632641.
  • 32
    Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997; 226: 248257.
  • 33
    Lieberman MD, Kilburn H, Lindsey M, et al. Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg 1995; 225: 638645.
  • 34
    Yeo CJ, Cameron JL, Lillemoe KD. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995; 221: 721731.
  • 35
    Harrison LE, Brennan MF. Portal vein resection for pancreatic adenocarcinoma. Surg Oncol Clin N Am 1998; 7: 165181.
  • 36
    Crile G, Jr. The advantages of bypass operations over radical pancreatoduodenectomy in the treatment of pancreatic carcinoma. Surg Gynecol Obstet 1970; 130: 10491053.
  • 37
    Shapiro TM. Adenocarcinoma of the pancreas: a statistical analysis of biliary bypass vs Whipple resection in good risk patients. Ann Surg 1975; 182: 715721.
  • 38
    Gudjonsson B. Cancer of the pancreas. 50 years of surgery. Cancer 1987; 60: 22842303.
  • 39
    Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4: 567579.
  • 40
    Lillemoe KD, Cameron JL, Kaufman HS, et al. Chemical splanchnicectomy in patients with unresectable pancreatic cancer. A prospective randomized trial. Ann Surg 1993; 217: 447455.
  • 41
    Anderson, Jr, Sorensen SM, Kruse A, et al. Randomised trial of endoscopic endoprosthesis versus operative bypass in malignant obstructive jaundice. Gut 1989; 30: 11321135.
  • 42
    Smith AC, Dowsett JF, Russell RC, et al. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction. Lancet 1994; 344: 16551660.
  • 43
    Bornman PC, Tobias R, Harries-Jones EP, et al. Prospective controlled trial of transhepatic biliary endoprosthesis versus bypass surgery for incurable carcinoma of the head of pancreas. Lancet 1986; 1: 6971.
  • 44
    Bakkevold KE, Arnesjo B, Dahl O, et al. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater–results of a controlled, prospective, randomised multicentre study. Eur J Cancer 1993; 29A: 698703.
  • 45
    Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999; 230: 776782.
  • 46
    Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 12001210.
  • 47
    Westerdahl J, Andren-Sandberg A, Ihse I. Recurrence of exocrine pancreatic cancer local orhepatic? Hepatogastroenterology 1993; 40: 384387.
  • 48
    Griffin JF, Smalley SR, Jewell W, et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer 1990; 66: 5661.
  • 49
    Ozaki H. Improvement of pancreatic cancer treatment from the Japanese experience in the 1980s. Int J Pancreatol 1992; 12: 59.
  • 50
    Tepper J, Nardi G, Sutt H. Carcinoma of the pancreas: review of MGH experience from 1963 to 1973. Analysis of surgical failure and implications for radiation therapy. Cancer 1976; 37: 15191524.
  • 51
    Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120: 899903.
  • 52
    Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987; 59: 20062010.
  • 53
    Whittington R, Bryer MP, Haller DG, et al. Adjuvant therapy of resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 1991; 21: 11371143.
  • 54
    Foo ML, Gunderson LL, Nagorney DM, et al. Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation ± 5 fluorouracil. Int J Radiat Oncol Biol Phys 1993; 26: 483489.
  • 55
    Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997; 225: 621633.
  • 56
    Demeure MJ, Doffek KM, Komorowski RA, et al. Molecular metastases in stage I pancreatic cancer: improved survival with adjuvant chemoradiation. Surgery 1998; 124: 663669.
  • 57
    Yeo TP, Hruban RH, Leach SD, et al. Pancreatic cancer. Curr Probl Cancer 2002; 26: 176275.
  • 58
    Mehta VK, Fisher GA, Ford JM, et al. Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer. Int J Radiat Oncol Biol Phys 2000; 48: 14831487.
  • 59
    Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001; 358: 15761585.
  • 60
    Abrams RA, Lillemoe KD, Piantadosi S. Continuing controversy over adjuvant therapy of pancreatic cancer. Lancet 2001; 358: 15651566.
  • 61
    Evans DB, Hess KR, Pisters PW. ESPAC-1 trial of adjuvant therapy for resectable adenocarcinoma of the pancreas. Ann Surg 2002; 236: 694.
  • 62
    Koshy MC, Landry JC, Cavanaugh SX, et al. A challenge to the therapeutic nihilism of ESPAC-1. Int J Radiat Oncol Biol Phys 2005; 61: 965966.
  • 63
    Breslin TM, Hess KR, Harbison DB, et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 2001; 8: 123132.
  • 64
    Wayne JD, Abdalla EK, Wolff RA, et al. Localized adenocarcinoma of the pancreas: the rationale for preoperative chemoradiation. Oncologist 2002; 7: 3445.
  • 65
    Hoffman JP, Lipsitz S, Pisansky T, et al. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998; 16: 317323.
  • 66
    White RR, Hurwitz HI, Morse MA, et al. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol 2001; 8: 758765.
  • 67
    Moutardier V, Giovanni M, Lelong B, et al. A phase II single institutional experience with pre-operative radiochemotherapy in pancreatic adenocarcinoma. Eur J Surg Oncol 2002; 28: 531539.
  • 68
    Magnin V, Moutardier V, Giovannini MH, et al. Neoadjuvant pre-operative chemoradiation in patients with pancreatic cancer. Int J Radiat Oncol Biol Phys 2003; 55: 13001304.
  • 69
    Todd KE, Gloor B, Lane JS, et al. Resection of locally advanced pancreatic cancer after downstaging with continuous infusion 5-fluorouracil, mitomycin-C, leucovorin and dipyridamole. J Gastrointest Surg 1998; 2: 159166.
  • 70
    Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomyfor adenocarcinoma of the pancreas. Arch Surg 1992; 127: 13351339.
  • 71
    Pisters PWT, Abbruzzese JL, Janjan NA, et al. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol 1998; 16: 38433850.
  • 72
    Pendurthi TK, Hoffman JP. Pre-operative versus postoperative chemoradiation for patients with resected pancreatic adenocarcinoma. Am Surg 1998; 64: 686692.
  • 73
    Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997; 5: 928937.
  • 74
    Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads [cedil]s 5-fluorouracil), and high dose radiation [cedil]s 5-fluorouracil. Gastrointestinal Tumor Study Group. Cancer 1981; 48: 17051710.
  • 75
    Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988; 80: 751755.
  • 76
    Moertel CG, Childs DS, Jr, Reitemeier RJ, et al. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969; 2: 865867.
  • 77
    Klaassen DJ, MacIntyre JM, Catton GE, et al. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil—an Eastern Cooperative Oncology Group study. J Clin Oncol 1985; 3: 373378.
  • 78
    Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2,2′-difluorode-oxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994; 12: 2934.
  • 79
    Carmichael J, Fink U, Russell RC, et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996; 73: 101105.
  • 80
    Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 24032413.
  • 81
    Lygidakis NJ, Sgourakis G, Georgia D, et al. Regional targeting chemoimmunotherapy in patients undergoing pancreatic resection in an advanced stage of their disease: a prospective randomized study. Ann Surg 2002; 236: 806813.
  • 82
    Nukui Y, Picozzi VJ, Traverso LW. Interferon based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 2000; 179: 367371.
  • 83
    Ceha HM, van Tienhoven G, Gouma DJ, et al. Feasibility and efficacy of high dose conformal radiotherapy for patients with locally advanced pancreatic carcinoma. Cancer 2000; 89: 22222229.
  • 84
    Horst E, Micke O, Moustakis C, et al. Conformal therapy for pancreatic cancer: variation of organ position due to gastrointestinal distention–implications for treatment planning. Radiology 222: 681686.
  • 85
    Fuss M, Salter BJ, Cavanaugh SX, et al. Daily ultrasound-based image-guided targeting for radiotherapy of upper abdominal malignancies. Int J Radiat Oncol Biol Phys 2004; 59: 12451256.
  • 86
    Fuss M, Wong A, Salter BJ, et al. Daily ultrasound-based image-guided intensity-modulated radiation therapy (IG-IMRT) for pancreatic carcinoma. Available at: http://www.asco.org. Accessed June 1, 2005.
  • 87
    Koong AC, Le QT, Ho A, et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2004; 58: 10171021.
  • 88
    Yamada S, Kato H, Yamaguchi K, et al. Carbon ion therapy for patients with localized, resectable adenocarcinoma of the pancreas. Available at: http://www.asco.org. Accessed June 1, 2005.
  • 89
    Intensity Modulated Radiation Therapy Collaborative Working Group. Intensity-modulated radiotherapy: Current status and issues of interest. Int J Radiat Oncol Biol Phys 2001; 51: 880914.
  • 90
    Zelefsky MJ, Fuks Z, Happersett L, et al. Clinical experience with intensity-modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 2000; 55: 241249.
  • 91
    Chao C, Deasy JO, Markman J, et al. Functional outcome of parotid gland sparing in patients with head and neck cancers receiving intensity-modulated (IMRT) or 3-D radiation therapy. Int J Radiat Oncol Biol Phys 2001; 49: 907916.
  • 92
    Sultanem K, Shu HK, Xia P, et al. Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: The University of California—San Francisco experience. Int J Radiat Oncol Biol Phys 2000; 48: 711722.
  • 93
    Landry JC, Yang GY, Ting JY, et al. Treatment of pancreatic cancer tumors with intensity modulated radiation therapy (IMRT) using the volume at risk approach (VARA): employing dose-volume histogram (DVH) and normal tissue complication probability (NTCP) to evaluate small bowel toxicity. Med Dosimetry 2002; 27: 121129.
  • 94
    Ben-Josef E, Shields A, Vayshampayan U, et al. Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Int J Radiat Oncol Biol Phys 2004; 59: 454459.
  • 95
    Bramhall SR, Neoptolemos JP, Stamp GW, et al. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J Pathol 1997; 182: 347355.
  • 96
    Koshiba T, Hosotani R, Wada M, et al. Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. Cancer 1998; 82: 642650.
  • 97
    Bramhall SR, Rosemurgy A, Brown PD, et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001; 19: 34473455.
  • 98
    Hess KR, Abbruzzese JL. Matrix metalloproteinase inhibition of pancreatic cancer: matching mechanism of action to clinical trial design. J Clin Oncol 2001; 19: 34453446.
  • 99
    Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727739.
  • 100
    Fujioka S, Yoshida K, Yanagisawa S, et al. Angiogenesis in pancreatic carcinoma: thymidinephosphorylase expression in stromal cells and intratumoral microvessel density as independentpredictors of overall and relapse-free survival. Cancer 2001; 92: 17881797.
  • 101
    Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocrine Rev 1997; 18: 425.
  • 102
    Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 23352342.
  • 103
    Crane CH, Ellis LM, Abbruzzese JL, et al. Phase I trial of bevacizumab (BV) with concurrent radiotherapy (RT) and capecitabine (CAP) in locally advanced pancreatic adenccarcinoma (PA). Available at: http://www.asco.org. Accessed June 1, 2005.
  • 104
    Yamanaka Y, Friess H, Kobrin MS, et al. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anti cancer Res 1993; 13: 565569.
  • 105
    Fan Z, Mendelsohn J. Therapeutic application of anti-growth factor receptor antibodies. Curr Opin Oncol 1998; 10: 6773.
  • 106
    Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anti cancer therapy. Clin Cancer Res 1997; 3: 2703.
  • 107
    Saltz LB, Meropol NJ, Loehrer PJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 12011208.
  • 108
    Abbruzzese JL, Rosenberg A, Xiong Q, et al. Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 2001; 20: 130.
  • 109
    Moore MJ, Goldstein D, Hamm J, et al. Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. Available at: http://www.asco.org. Accessed June 1, 2005.
  • 110
    Gilliam AD, Topuzov EG, Garin AM, et al. Randomised, double blind, placebo-controlled, multi-centre, group-sequential trial of G17DT for patients with advanced pancreatic cancer unsuitable or unwilling to take chemotherapy. J Clin Oncol 2004; 22: 2511.
  • 111
    Brett BT, Smith SC, Bouvier CV, et al. Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J Clin Oncol 2002; 20: 42254231.
  • 112
    Shapiro J, Marshall J, Karasek P, et al. G17DT+gemcitabine [Gem] versus placebo+Gem in untreated subjects with locally advanced, recurrent, or metastatic adenocarcinoma of the pancreas: Results of a randomized, double-blind, multinational, multicenter study. Available at: http://www.asco.org. Accessed June 1, 2005.
  • 113
    Jaffee EM, Hruban RH, Biedrzycki B, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001; 19: 145156.